JAK2 and myeloproliferative disorder: Examples include the inhibition of the epidermal growth-factor (EGF)receptors, over-expressed in many solid tumors, and inhibition of Jak2 orBcr-Abl in myeloproliferative disease and leukemia [49]–[52].